nach oben

18.05.2024 | Original Article

The effect of hormone therapy on physiological uptake of the endometrium on [¹⁸F]F-FDG PET in postmenopausal women

verfasst von: Ryusuke Nakamoto, Masahiro Yakami, Tomomi W. Nobashi, Hiroyoshi Isoda, Yuji Nakamoto

Erschienen in: Annals of Nuclear Medicine

Einloggen, um Zugang zu erhalten

Abstract

Objective

The effects of hormonal therapy, estrogen-based hormone replacement therapy (HRT), and anti-tumor hormone therapy, such as tamoxifen, on the physiological uptake of the endometrium on 2-deoxy-2[¹⁸F]fluoro-d-glucose ([¹⁸F]F-FDG) positron emission tomography (PET) in postmenopausal women have not been determined. We explored the effect of hormone therapy, particularly HRT, on physiological uptake in the endometrium of postmenopausal women.

Materials and methods

Postmenopausal women receiving hormone therapy who underwent cancer screening using PET/computed tomography (CT) between June 2016 and April 2023 were included in the hormone therapy group (n = 21). Postmenopausal women with no history of hormone therapy were included in the control group (n = 49). First, the physiological endometrial uptake at menopausal age and at least 1 year thereafter was compared quantitatively (SUVmax) and qualitatively (4-point scale) in the control group, to assess when the endometrium ceased to show significant physiological [¹⁸F]F-FDG uptake after menopause. Endometrial uptake was compared between the hormone therapy and control groups. The association between HRT duration (months) and endometrial uptake (SUVmax) was evaluated. Endometrial thickness, measured using transvaginal ultrasonography, was also compared between the two groups.

Results

Endometrial uptake was significantly reduced both qualitatively and quantitatively (P < 0.05) at least 1 year after menopause in control patients, by which time most women (89.8%) no longer had significant endometrial uptake. The hormone therapy group (n = 21) showed higher FDG uptake in the endometrium compared to the control group (median SUVmax: 2.3 vs 1.9, P = 0.0011), as well as a higher visual score (P < 0.0001). HRT duration did not correlate with endometrial uptake (P = 0.097). Endometrial thickness in the hormone therapy group was significantly thicker than in the control group (median: 3.9 mm vs 1.8 mm, P = 0.002).

Conclusion

Hormone therapy may affect physiological uptake in the endometrium in postmenopausal women.

Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872–81. https://doi.org/10.1001/jama.288.7.872.CrossRefPubMed

Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545–53. https://doi.org/10.7326/0003-4819-130-7-199904060-00002.CrossRefPubMed

Lee SR, Cho MK, Cho YJ, Chun S, Hong S-H, Hwang KR, et al. The 2020 menopausal hormone therapy guidelines. J Menopaus Med. 2020;26:69.CrossRef

Hirota K, Honjo H, Shintani M. Factors affecting menopause. Adv Obstet Gynecol. 1995;47:389–92.

Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas. 1996;23:47–53. https://doi.org/10.1016/0378-5122(95)00952-3.CrossRefPubMed

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. https://doi.org/10.1001/jama.288.3.321.CrossRefPubMed

Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas. 2014;79:287–91. https://doi.org/10.1016/j.maturitas.2014.07.002.CrossRefPubMed

Peng W, Adams J, Hickman L, Sibbritt DW. Complementary/alternative and conventional medicine use amongst menopausal women: results from the Australian Longitudinal Study on Women’s Health. Maturitas. 2014;79:340–2. https://doi.org/10.1016/j.maturitas.2014.08.002.CrossRefPubMed

Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. Maturitas. 2016;84:81–8. https://doi.org/10.1016/j.maturitas.2015.11.010.CrossRefPubMed

10.

Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. Radiology. 1995;197:603–8.CrossRefPubMed

11.

Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266–71.PubMed

12.

Research on the menopause in the. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1990;1996(866):1–107.

13.

Liu Y. Benign ovarian and endometrial uptake on FDG PET-CT: patterns and pitfalls. Ann Nucl Med. 2009;23:107–12. https://doi.org/10.1007/s12149-008-0227-z.CrossRefPubMed

14.

Lakhani A, Khan SR, Bharwani N, Stewart V, Rockall AG, Khan S, et al. FDG PET/CT pitfalls in gynecologic and genitourinary oncologic imaging. Radiographics. 2017;37:577–94. https://doi.org/10.1148/rg.2017160059.CrossRefPubMed

15.

Julian A, Payoux P, Rimailho J, Paynot N, Esquerre J. Uterine uptake of F-18 FDG on positron emission tomography induced by an intrauterine device: unusual pitfall. Clin Nucl Med. 2007;32:128–9. https://doi.org/10.1097/01.rlu.0000251870.33485.69.CrossRefPubMed

16.

Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst. 1999;91:1131–7. https://doi.org/10.1093/jnci/91.13.1131.CrossRefPubMed

17.

Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18.CrossRefPubMed

18.

Noci I, Borri P, Scarselli G, Chieffi O, Bucciantini S, Biagiotti R, et al. Uterus and endometrium: morphological and functional aspects of the endometrium of asymptomatic post-menopausal women: does the endometrium really age? Hum Reprod. 1996;11:2246–50.CrossRefPubMed

19.

von Wolff M, Ursel S, Hahn U, Steldinger R, Strowitzki T. Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab. 2003;88:3885–92.CrossRef

20.

Frolova AI, Moley KH. Quantitative analysis of glucose transporter mRNAs in endometrial stromal cells reveals critical role of GLUT1 in uterine receptivity. Endocrinology. 2011;152:2123–8.CrossRefPubMedPubMedCentral

21.

Medina RA, Meneses AM, Vera JC, Gúzman C, Nualart F, Rodriguez F, et al. Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells. J Endocrinol. 2004;182:467–78.CrossRefPubMed

22.

Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549–56. https://doi.org/10.1007/s00259-004-1703-x.CrossRefPubMed

23.

Tamura I, Fujimura T, Doi-Tanaka Y, Takagi H, Shirafuta Y, Kajimura T, et al. The essential glucose transporter GLUT1 is epigenetically upregulated by C/EBPβ and WT1 during decidualization of the endometrium. J Biol Chem. 2021;297:101150.CrossRefPubMedPubMedCentral

24.

Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology. 2000;214:29–38. https://doi.org/10.1148/radiology.214.1.r00ja4429.CrossRefPubMed

25.

Vranjesevic D, Schiepers C, Silverman DH, Quon A, Villalpando J, Dahlbom M, et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med. 2003;44:1238–42.PubMed

26.

Nagata C, Matsushita Y, Shimizu H. Prevalence of hormone replacement therapy and user’s characteristics: a community survey in Japan. Maturitas. 1996;25:201–7. https://doi.org/10.1016/s0378-5122(96)01067-5.CrossRefPubMed

Titel: The effect of hormone therapy on physiological uptake of the endometrium on [18F]F-FDG PET in postmenopausal women
verfasst von: Ryusuke Nakamoto
Masahiro Yakami
Tomomi W. Nobashi
Hiroyoshi Isoda
Yuji Nakamoto
Publikationsdatum: 18.05.2024
Verlag: Springer Nature Singapore
Erschienen in: Annals of Nuclear Medicine
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-024-01941-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The effect of hormone therapy on physiological uptake of the endometrium on [¹⁸F]F-FDG PET in postmenopausal women

Abstract

Objective

Materials and methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten